The nanoparticle drug delivery industry focuses on developing advanced methods for transporting therapeutic agents effectively to targeted areas in the body. This sector is vital as it aids in improving the efficacy and safety of treatments for various conditions, especially cancer and rare diseases. Companies in this space utilize innovative technologies like lipid nanoparticles and biodegradable polymers to enhance drug delivery while minimizing side effects. With a growing emphasis on personalized medicine and the rise of mRNA therapies, the industry is poised for rapid expansion, emphasizing partnerships between biotech firms and leading pharmaceutical companies.


The list of nanoparticle drug delivery companies includes a mix of established firms and startups. Primarily based in countries like Canada, Germany, and the United States, these companies vary in size, employing between 11 and 500 people. Most were founded in the last two decades, focusing on technologies such as lipid nanoparticle systems and innovative drug delivery platforms. Notable players include Precision NanoSystems and Acuitas Therapeutics, showcasing specialization in genomic medicines and LNP technology, respectively.


Top 21 Nanoparticle Drug Delivery Companies


1. Precision NanoSystems is now part of Cytiva


Precision NanoSystems, now part of Cytiva, is a biotechnology firm based in Vancouver, British Columbia, that specializes in lipid nanoparticle technologies aimed at genomic medicines. Founded in 2010, the company has carved out a niche in the development of mRNA vaccines and therapeutics. They offer a range of services, from formulation development to cGMP manufacturing, primarily serving biopharmaceutical companies engaged in drug development for diseases such as cancer and rare diseases. Their proprietary NanoAssemblr technology facilitates the efficient production of lipid nanoparticles, which are essential for delivering nucleic acid-based therapies. Precision NanoSystems has established itself as a key player in the field, providing solutions that accelerate the transition of genomic medicines from concept to clinical application.


2. Acuitas Therapeutics

  • Website: acuitastx.com
  • Ownership type: Private
  • Headquarters: Vancouver, British Columbia, Canada
  • Employee distribution: Canada 100%
  • Founded year: 2009
  • Headcount: 51-200
  • LinkedIn: acuitastx

Acuitas Therapeutics is a biotechnology company based in Vancouver, British Columbia, founded in 2009. The company specializes in developing lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics. Acuitas collaborates with pharmaceutical and biotechnology firms, as well as academic institutions, to advance innovative therapies aimed at addressing unmet clinical needs. Their LNP technology has been clinically validated, notably through its use in Onpattro™, an RNAi therapeutic approved for treating transthyretin amyloidosis. Acuitas is also recognized for its role in the development of the COVID-19 vaccine COMIRNATY®, in partnership with BioNTech and Pfizer. The company has synthesized over 500 novel cationic lipids, enhancing the potency and safety of their LNP carriers. With a strong intellectual property portfolio and a commitment to advancing nucleic acid medicines, Acuitas Therapeutics is positioned as a key player in the field of nanoparticle drug delivery.


3. Genevant Sciences

  • Website: genevant.com
  • Ownership type: Private
  • Headquarters: Vancouver, British Columbia, Canada
  • Employee distribution: Canada 96%, United States (USA) 4%
  • Founded year: 2018
  • Headcount: 11-50
  • LinkedIn: genevant

Genevant Sciences Corporation, founded in 2018 and based in Vancouver, British Columbia, is a biotechnology firm focused on nucleic acid delivery technologies. The company specializes in lipid nanoparticles (LNPs), which are crucial for the effective delivery of mRNA and siRNA therapies. With a strong patent estate of over 700 patents, Genevant has established itself as a key player in the field of nucleic acid drug delivery. Their technology has been validated through numerous clinical programs, and they have collaborated with notable companies like Novo Nordisk and Repair Biotechnologies to develop innovative therapies. Genevant's commitment to addressing the challenges of nucleic acid delivery underscores its relevance in the biotechnology sector.


4. Apurano Pharmaceuticals GmbH


Apurano Pharmaceuticals GmbH, founded in 2014 and based in Warngau, Bavaria, Germany, is a private pharmaceutical and biotechnology firm. The company is dedicated to advancing smart bio-nanotechnology, with a primary focus on developing innovative products that enhance drug delivery and improve therapeutic efficacy. Apurano's work is aimed at providing healthcare providers and researchers with cutting-edge solutions that leverage nanotechnology to optimize treatment outcomes. With a small team of 11-50 employees, the company operates entirely within Germany, reflecting a concentrated effort in its local market. Although there is no reported funding, Apurano continues to pursue its mission of innovation in the pharmaceutical sector, particularly in the area of nanoparticle drug delivery.


5. Nanomi

  • Website: nanomi.com
  • Ownership type: Private
  • Headquarters: Oldenzaal, Overijssel, Netherlands
  • Employee distribution: Netherlands 100%
  • Founded year: 2004
  • Headcount: 11-50
  • LinkedIn: nanomi

Nanomi, based in Oldenzaal, Netherlands, is a pharmaceutical company that specializes in drug delivery systems, particularly long-acting release injectable medicines. Founded in 2004, the company has developed proprietary Microsieve technology, which enables the production of uniform microspheres and nanoparticles. This technology is crucial for creating biodegradable particles that encapsulate active pharmaceutical compounds, allowing for tailored release profiles. Nanomi serves pharmaceutical companies and healthcare providers, emphasizing innovation and quality to enhance patient compliance and therapeutic outcomes. As a subsidiary of Lupin Limited, Nanomi operates within a larger framework that supports its research and development efforts, positioning it as a significant player in the field of complex injectables.


6. OncoNano Medicine, Inc.

  • Website: onconano.com
  • Ownership type: Venture Capital
  • Headquarters: Southlake, Texas, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: Series B, $18.4M, October 2021
  • Founded year: 2014
  • Headcount: 11-50
  • LinkedIn: onconano-medicine

OncoNano Medicine, Inc., founded in 2014 and based in Southlake, Texas, is a biotechnology firm dedicated to improving cancer treatment through innovative drug delivery systems. The company specializes in oncology therapeutics, leveraging its proprietary ON-BOARD™ nanotechnology platform to enhance the precision of drug delivery to tumors. This platform utilizes ultra pH-sensitive polymeric micelles that respond to the acidic environment of tumors, allowing for targeted delivery of therapeutic agents while minimizing systemic exposure. OncoNano is currently involved in clinical trials to validate its therapies, including ONM-501, a nanoparticle-based dual-activating STING agonist, and Pegsitacianine, a pH-sensitive fluorescent nanoprobe. The company has secured significant funding, including an $18.4 million Series B round in 2021, which supports its ongoing research and development efforts in the oncology sector.


7. ACM Biolabs

  • Website: acmbiolabs.com
  • Ownership type: Venture Capital
  • Headquarters: Singapore
  • Employee distribution: Singapore 100%
  • Latest funding: $6.8M, September 2022
  • Founded year: 2013
  • Headcount: 11-50
  • LinkedIn: acm-biolabs

ACM Biolabs, founded in 2013 and based in Singapore, is a biotechnology firm focused on creating innovative drug delivery systems and therapeutics. The company specializes in polymer-based nanoparticle platforms aimed at enhancing vaccine and therapy delivery for various diseases. Their proprietary technology, the Tunable Platform (ATP™), allows for the delivery of multiple drug payloads, including oligonucleotides, small molecules, proteins, and mRNA. This platform is notable for its thermostability, enabling mRNA storage at 4°C, which is a significant improvement over traditional lipid nanoparticle systems that require ultra-low temperatures. ACM Biolabs has been involved in clinical trials, including a Phase 1 trial for a COVID-19 booster vaccine, demonstrating their active role in the industry. The company has also received $6.8 million in funding as of September 2022, indicating strong investor confidence in their technology and potential.


8. Abogen Biosciences


Abogen Biosciences, founded in 2019 and based in Suzhou, Jiangsu, China, is a private equity-backed biopharmaceutical company focused on the development of mRNA-based drugs. The company has established a proprietary technology platform that includes advanced mRNA design, synthesis, and lipid nanoparticle (LNP) delivery systems. Abogen is particularly noted for its work in creating innovative therapies aimed at infectious diseases and cancer. Their product pipeline includes the ARCoV mRNA vaccine, which is recognized as China's first approved mRNA vaccine. The company has successfully raised significant funding, including a $300 million Series C round in late 2021, which underscores its growth potential and commitment to advancing mRNA technology in the pharmaceutical industry.


9. Nanovex Biotechnologies


Nanovex Biotechnologies is a private biotechnology company founded in 2014, based in Honduras, with a workforce of around 23 employees primarily located in Spain. The company specializes in drug delivery systems and nanotechnology solutions, offering products such as liposomes and synthetic exosomes. Their mission is to improve drug efficacy and safety through advanced delivery mechanisms, addressing common challenges in drug development like low efficacy, toxicity, and poor bioavailability. Nanovex provides customizable solutions tailored to the needs of their clients in the pharmaceutical and cosmetic sectors. They have also received funding through grants, which supports their ongoing research and development efforts in the field of nanobiotechnology.


10. Biotechna S.A.

  • Website: bsbiotechna.com
  • Ownership type: Private
  • Headquarters: Kraków, Lesser Poland Voivodeship, Poland
  • Employee distribution: Poland 100%
  • Founded year: 2019
  • Headcount: 11-50
  • LinkedIn: bs-biotechna

Biotechna S.A., founded in 2019 and based in Kraków, Poland, is a biotechnology firm dedicated to the development of innovative cancer therapies. The company specializes in targeted therapies that leverage nanotechnology and siRNA technology, aiming to meet significant medical needs in oncology. With a team of highly skilled scientists in nanochemistry, biology, and medicine, Biotechna is focused on creating new drug synergies and advancing drug delivery systems. Their proprietary nanoparticle platform is designed to enhance the stability and delivery of therapeutic nucleic acids, addressing challenges in treating various types of cancer. Biotechna's pipeline includes over 20 confirmed high-efficacy synergies across multiple cancer types, showcasing their commitment to improving patient access to cutting-edge therapies. The company collaborates with healthcare providers and pharmaceutical companies, positioning itself as a key player in the oncology sector.


11. RS Research

  • Website: rsresearch.net
  • Ownership type: Corporate
  • Headquarters: Pendik, İstanbul, Turkey
  • Employee distribution: Turkey 100%
  • Latest funding: Other (Grant), $109,000, March 2024
  • Founded year: 2015
  • Headcount: 11-50
  • LinkedIn: rs-research

RS Research is a biotechnology start-up based in Pendik, İstanbul, Turkey, founded in 2015. The company is dedicated to discovering and developing smart nanomedicines aimed at enhancing targeted chemotherapy. Their innovative drug delivery technology is designed to improve treatment efficacy while minimizing side effects for cancer patients. RS Research has developed a proprietary platform technology known as Sagitta®, which allows for the design of targeted drug candidates across various oncology indications. The company has made significant strides in clinical development, with their lead candidate, RS-0139, currently undergoing Phase I trials. They have also secured funding, including a recent grant of approximately $108,734 in March 2024, to support their research and development efforts. Their primary customers include healthcare providers and patients seeking advanced cancer therapies, positioning them as a relevant player in the biotechnology and nanoparticle drug delivery sectors.


12. DIVERSA Technologies


DIVERSA Technologies, based in Santiago De Compostela, A Coruña, Spain, is a biotechnology company founded in 2022. The firm specializes in drug delivery systems, focusing on innovative nanoparticle formulations tailored for various therapeutic molecules. Their primary clientele includes researchers and pharmaceutical companies, indicating a strong alignment with industry needs. DIVERSA's technology aims to overcome biological barriers in drug development, enhancing the efficiency of new therapies. The company offers a range of products, including delivery systems for small molecules, proteins, peptides, and mRNA, showcasing their versatility in addressing different therapeutic challenges. As a spin-off from the Santiago de Compostela Health Research Institute, DIVERSA is positioned to leverage academic insights and research capabilities to drive advancements in drug delivery.


13. InnoMedica Holding AG

  • Website: innomedica.com
  • Ownership type: Venture Capital
  • Headquarters: Bern, Bern, Switzerland
  • Employee distribution: Switzerland 96%, Germany 4%
  • Latest funding: $16.2M, November 2021
  • Founded year: 2000
  • Headcount: 51-200
  • LinkedIn: innomedica-ag

InnoMedica Holding AG, based in Bern, Switzerland, is a pharmaceutical company that specializes in the development of innovative drug delivery systems through nanocarrier technology. Founded in 2000, the company has shifted its focus towards creating targeted therapies for oncology and neurology, addressing the pressing need for effective treatments that minimize side effects. InnoMedica operates a state-of-the-art GMP manufacturing facility and offers Contract Research, Development, and Manufacturing Organization (CRDMO) services, catering to healthcare providers and pharmaceutical companies. The company has made significant strides in its product pipeline, with ongoing clinical studies for its liposomal formulations aimed at improving the delivery of established drugs like Doxorubicin and developing new treatments for neurodegenerative diseases such as Parkinson's. InnoMedica has also secured funding, with a reported amount of approximately 16.2 million Swiss Francs in late 2021, indicating investor confidence in their innovative approach and growth potential.


14. GP-Pharm

  • Website: gp-pharm.com
  • Ownership type: Private
  • Headquarters: L'Hospitalet De Llobregat, Catalonia, Spain
  • Employee distribution: Spain 53%, Argentina 45%, Uruguay 3%
  • Founded year: 2000
  • Headcount: 51-200
  • LinkedIn: lab.-gp-pharm

GP-Pharm, founded in 2000 and based in L'Hospitalet De Llobregat, Catalonia, Spain, is a private pharmaceutical company that focuses on the development and manufacturing of injectable drugs. The company has carved a niche in oncology, urology, and women's health, providing contract manufacturing and development services. GP-Pharm is particularly noted for its expertise in drug delivery systems, including microencapsulation technologies that utilize liposomes and lipid nanoparticles. Their operations span from research and development to market launch, ensuring a comprehensive approach to pharmaceutical innovation. The company has established a strong international presence, collaborating with various pharmaceutical firms to enhance their product offerings. GP-Pharm's facilities have been approved by multiple regulatory agencies, underscoring their commitment to quality and compliance in drug manufacturing.


15. ANP Technologies, Inc.

  • Website: anptinc.com
  • Ownership type: Private
  • Headquarters: United States (USA)
  • Employee distribution: United States (USA) 100%
  • Founded year: 2002
  • Headcount: 11-50
  • LinkedIn: anp-technologies-inc.

ANP Technologies, Inc. is a biotechnology firm based in Newark, Delaware, founded in 2002. The company specializes in the development of nano-therapeutics and drug delivery systems, catering primarily to pharmaceutical companies and research institutions. Their product offerings include innovative solutions for immunogenicity testing and biodefense, alongside a strong emphasis on therapeutic drug delivery. ANP has made significant strides in the field of cancer treatment, having developed nanoencapsulated therapies such as paclitaxel, which is currently undergoing clinical trials. Their collaborations with Fulgent Pharma and Moffitt Cancer Center highlight their commitment to advancing cancer therapies through targeted drug delivery. Additionally, ANP has a portfolio that includes antibody therapies and mRNA-based vaccines, showcasing their active role in the biopharmaceutical industry.


16. OxSonics Therapeutics

  • Website: oxsonics.com
  • Ownership type: Venture Capital
  • Headquarters: Oxford, England, United Kingdom (UK)
  • Employee distribution: United Kingdom (UK) 100%
  • Latest funding: Series B, $13.1M, July 2020
  • Founded year: 2013
  • Headcount: 11-50
  • LinkedIn: oxsonics-limited

OxSonics Therapeutics, founded in 2013 and based in Oxford, UK, is a biotechnology company focused on developing innovative cancer therapies. The company is known for its proprietary SonoTran® platform, which enhances the delivery of anti-cancer drugs to solid tumors, addressing a critical limitation in current cancer treatments. OxSonics collaborates with pharmaceutical and biotech firms to optimize cancer therapies through advanced drug delivery solutions. The company has received significant venture capital funding, with a Series B round totaling approximately £13 million in July 2020. This funding supports their ongoing development programs and clinical trials, particularly in enhancing the efficacy of existing oncology agents. OxSonics is committed to improving patient outcomes by making cancer treatments more effective and less toxic.


17. Kernal Biologics

  • Website: kernalbio.com
  • Ownership type: Venture Capital
  • Headquarters: Cambridge, Massachusetts, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: Series A, $25.0M, July 2022
  • Founded year: 2016
  • Headcount: 11-50
  • LinkedIn: kernal-biologics-inc.

Kernal Biologics, founded in 2016 and based in Cambridge, Massachusetts, is a biotechnology firm specializing in mRNA therapeutics aimed at treating serious illnesses, particularly cancer. The company has developed proprietary mRNA technologies that enhance the selective targeting of diseased cells, significantly reducing off-target effects. Kernal's innovative approach includes a clinically validated lipid nanoparticle (LNP) delivery system that ensures the mRNA reaches the appropriate tissues and cells. Their clientele includes healthcare providers and pharmaceutical companies seeking advanced solutions to improve patient outcomes. In July 2022, Kernal Biologics secured $25 million in Series A funding, which underscores their potential and recognition in the industry. The company has received accolades for its advancements and operates with a team of experts from prestigious institutions, further solidifying its position in the biotechnology sector.


18. Tiba Biotech

  • Website: tiba.bio
  • Ownership type: Private
  • Headquarters: Cambridge, Massachusetts, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: January 2020
  • Founded year: 2016
  • Headcount: 11-50
  • LinkedIn: tiba-biotech

Tiba Biotech, founded in 2016 and based in Cambridge, Massachusetts, is a biotechnology firm dedicated to advancing RNA vaccines and therapeutics. The company emerged from a five-year research initiative at the Massachusetts Institute of Technology (MIT) and the Whitehead Institute, focusing on innovative RNA delivery methods. Tiba Biotech has developed a fully biodegradable nanoparticle delivery platform designed to improve the safety and effectiveness of RNA medicines. Their technology aims to overcome the limitations of traditional lipid nanoparticles, which have been associated with toxicity and inflammation. Tiba's research has led to significant advancements in RNA design and delivery, with applications spanning vaccines for infectious diseases, immuno-oncology, and gene therapy. The company has received funding from various organizations, including the National Institutes of Health (NIH) and the Bill and Melinda Gates Foundation, to support their innovative projects. Tiba Biotech's commitment to addressing public health challenges through cutting-edge technology positions them as a notable player in the biotechnology sector.


19. Nuntius Therapeutics

  • Website: nuntiustx.com
  • Ownership type: Venture Capital
  • Headquarters: London, England, United Kingdom (UK)
  • Employee distribution: United Kingdom (UK) 100%
  • Latest funding: Pre-seed, $125,000, March 2021
  • Founded year: 2021
  • Headcount: 1-10
  • LinkedIn: nuntius-therapeutics

Nuntius Therapeutics is a biotechnology firm based in London, UK, founded in 2021. The company specializes in developing transformative mRNA therapies aimed at treating life-threatening diseases, including cancer, lung diseases, and neurodegenerative disorders. Nuntius leverages proprietary delivery technology that features programmable, scalable, and non-immunogenic nanocarriers, which are designed to target specific tissues and cell types effectively. Their innovative approach is further enhanced by machine learning models that predict carrier quality and performance, allowing for the selection of optimal delivery systems from a vast library of candidates. Recently, Nuntius has gained attention for its partnership with Taiho Pharmaceutical, focusing on the development of next-generation mRNA therapies, highlighting their active role in the pharmaceutical landscape. The company operates with a small team of dedicated scientists and entrepreneurs, reflecting a nimble and focused approach to drug development.


20. EnGeneIC

  • Website: engeneic.com
  • Ownership type: Venture Capital
  • Headquarters: Lane Cove West, New South Wales, Australia
  • Employee distribution: Australia 100%
  • Latest funding: $150,000, April 2017
  • Founded year: 2001
  • Headcount: 11-50
  • LinkedIn: engeneic

EnGeneIC is a biopharmaceutical company based in Lane Cove West, New South Wales, Australia, founded in 2001. The company is dedicated to developing targeted anti-cancer therapies through its proprietary EDV™ nanocell platform. This innovative technology allows for the direct targeting of tumors while enhancing the immune response and minimizing toxicity to patients. EnGeneIC's research and development efforts are focused on delivering effective treatments for various types of cancer, and the company has established a robust pipeline of clinical trials. Notably, EnGeneIC has been recognized for its innovative approach, receiving awards for its contributions to biotechnology in Australia. The company operates with a small team of around 40 employees and has secured funding to support its initiatives, with the last reported funding amounting to $150,000 in April 2017. EnGeneIC's commitment to advancing cancer therapies positions it as a relevant player in the field of nanoparticle drug delivery.


21. Certest Pharma

  • Website: pharma.certest.es
  • Ownership type: Private
  • Headquarters: Villanueva De Gállego, Aragon, Spain
  • Employee distribution: Spain 100%
  • Founded year: 2021
  • Headcount: 201-500
  • LinkedIn: certest-pharma

Certest Pharma, founded in 2021 and based in Villanueva De Gállego, Aragon, Spain, is a private pharmaceutical company that focuses on advanced lipid nanoparticle technology and RNA therapies. The company aims to provide innovative solutions for drug delivery and vaccine development, primarily serving pharmaceutical companies and research institutions. Certest Pharma's multidisciplinary team consists of experienced scientists who are dedicated to tackling global health challenges through research and development. They specialize in synthesizing lipids, designing RNA sequences, and developing LNP compositions tailored for targeted delivery. Their expertise in ionizable lipids is particularly noteworthy, as these components are essential for enhancing the stability and efficiency of therapeutic agents. Certest Pharma actively seeks partnerships and collaborations to advance therapeutic innovation, demonstrating their commitment to improving healthcare outcomes.



Nanoparticle Drug Delivery Insights: Key Companies


CompanyHeadquarterSizeFoundedOwnership
Precision NanoSystems is now part of CytivaVancouver, British Columbia, Canada51-2002010Corporate
Acuitas TherapeuticsVancouver, British Columbia, Canada51-2002009Private
Genevant SciencesVancouver, British Columbia, Canada11-502018Private
Apurano Pharmaceuticals GmbHWarngau, Bavaria, Germany11-502014Private
NanomiOldenzaal, Overijssel, Netherlands11-502004Private
OncoNano Medicine, Inc.Southlake, Texas, United States (USA)11-502014Venture Capital
ACM BiolabsSingapore11-502013Venture Capital
Abogen BiosciencesSuzhou, Jiangsu, China201-5002019Private Equity
Nanovex BiotechnologiesHonduras11-502014Private
Biotechna S.A.Kraków, Lesser Poland Voivodeship, Poland11-502019Private
RS ResearchPendik, İstanbul, Turkey11-502015Corporate
DIVERSA TechnologiesSantiago De Compostela, A Coruña, Spain1-102022Private
InnoMedica Holding AGBern, Bern, Switzerland51-2002000Venture Capital
GP-PharmL'Hospitalet De Llobregat, Catalonia, Spain51-2002000Private
ANP Technologies, Inc.United States (USA)11-502002Private
OxSonics TherapeuticsOxford, England, United Kingdom (UK)11-502013Venture Capital
Kernal BiologicsCambridge, Massachusetts, United States (USA)11-502016Venture Capital
Tiba BiotechCambridge, Massachusetts, United States (USA)11-502016Private
Nuntius TherapeuticsLondon, England, United Kingdom (UK)1-102021Venture Capital
EnGeneICLane Cove West, New South Wales, Australia11-502001Venture Capital
Certest PharmaVillanueva De Gállego, Aragon, Spain201-5002021Private


Want to Find More Nanoparticle Drug Delivery Companies?

If you want to find more companies that offer innovative delivery systems and therapeutic solutions for diseases you can do so with Inven. This list was built with Inven and there are hundreds of companies like these globally.

With Inven you'll also get to know the company's:

  • Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
  • Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
  • Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!